<DOC>
	<DOCNO>NCT00150111</DOCNO>
	<brief_summary>Aim : In phase II pilot study encompass 20 patient Graves ’ disease evaluate effect rituximab : 1 . Biochemically assess marker disease activity ( free T4 , free T3 , TSH , TSH-receptor antibody , anti-TPO )</brief_summary>
	<brief_title>Rituximab Treatment Graves ' Disease</brief_title>
	<detailed_description>Background Rituximab chimeric murine/human anti-CD20 monoclonal antibody originally introduce clinic year ago treatment malignant lymphoma . The antibody IgG1 kappa immunoglobulin contain murine light-and heavy chain variable region sequence human constant region sequence . The Fab domain rituximab bind CD20 antigen B lymphocytes . Possible mechanism cell lysis include complement-dependent cytotoxicity , antibody-dependent cellular cytotoxicity , induction apoptosis . The mechanism ( ) behind favourable response rituximab autoimmune cytopenia unsettle . A depletion peripheral blood B cell occur one antibody infusion . Accordingly , propose opsonize CD20+ B cell inhibit saturate macrophage Fc-receptor function thereby clearance IgG-coated blood cell reticuloendothelial cell . Suppression auto reactive B-cell clone may another potential mechanism . Most recently several study show rituximab– also effective treatment various autoimmune cytopenia autoimmune diseases - idiopathic thrombocytopenic purpura ( ITP ) , warm cold autoimmune haemolytic anemia , autoimmune neutropenia , pure red cell aplasia , Wegener ’ granulomatosis , systemic lupus erythematosus , membranous glomerulonephritis , rheumatoid arthritis - , include disorder consider primarily disease elicit aberrant T-cell response , e.g. , rheumatoid arthritis . However , recently importance B-cell pathogenesis autoimmune disorder debate emphasized . Graves ’ disease autoimmune disease B- T-cells activate participate pathogenesis . However , B-cell activation production IgG – thyroid-stimulating antibody , bind activate thyrotropin receptor thyroid cell prerequisite development Graves ’ hyperthyroidism . The thyroid-stimulating antibody cause thyroid hypersecretion , hypertrophy hyperplasia thyroid follicles ultimately diffuse goiter together clinical hyperthyroidism . In addition thyroid-stimulating antibody thyroglobulin thyroid peroxidase also produce Graves ’ disease . The pathogenesis clinical feature disease – ophthalmopathy localize dermopathy myxedema – far less elucidated . It propose ophthalmopathy develops consequent autoimmune response thyrotropin receptor , also express preadipocyte subpopulation orbital fibroblast . The treatment Graves ’ disease include antithyroid drug , radioactive iodine surgery . All three treatment modality associate adverse effect side-effects . The serious complication antithyroid drug agranulocytosis less frequently acute hepatic necrosis , cholestatic hepatitis vasculitis . As treatment radioactive iodine therapy may worsen ophthalmopathy . In addition , treatment follow hypothyroidism large proportion patient . Based upon mentioned observation effective response many patient otherwise refractory autoimmune disorder pathogenetic concept Graves ’ disease disorder elicit auto antibody stimulate thyrotropin receptor thyroid cell ( hyperthyroidism goiter ) similar antigen orbit ( ophthalmopathy ) hypothesis B-cell depletion rituximab may efficacious therapy reduce abolish production auto antibody responsible Graves ’ disease . Aim study : In phase II pilot study encompass 20 patient Graves ’ disease evaluate effect rituximab : 1 . Biochemically assess marker disease activity ( free T4 , free T3 , TSH , TSH-receptor antibody , anti-TPO ) Study design Material method 20 patient recent onset untreated Graves ’ disease start antithyroid treatment ( methimazole ) . When euthyroidism reach – define normal thyroid parameter ( free T4 , free T3 , TSH ) – patient randomise +/- rituximab treatment . Afterwards , 2 patient group follow 1 year : - 10 euthyroid patient treat 4 week rituximab , antithyroid treatment discontinue . - 10 euthyroid patient receive rituximab antithyroid treatment discontinue 4 week . Effect parameter Differences relapse , remission rate 3 , 6 , 9 12 month follow up/ time relapse assess : • Biochemistry ( free T4 , free T3 , TSH , TSH-receptor antibody , anti-TPO ) Treatment Rituximab dose 375 mg/m² , administer iv . Infusion week 4 week . Premedication paracetamol 1g p.o . tavestin 2 mg i.v . give 30-60 min . infusion .</detailed_description>
	<mesh_term>Graves Disease</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Graves Ophthalmopathy</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Graves´ disease Adequate anticonception woman . Performance status &gt; 2 Previous rituximab treatment Immunosuppressive treatment Serious concomitant disease Active infection Pregnancy / breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>Graves disease</keyword>
	<keyword>thyroid</keyword>
	<keyword>ophthalmopathy</keyword>
	<keyword>autoimmunity</keyword>
	<keyword>B lymphocyte depletion</keyword>
	<keyword>rituximab</keyword>
	<keyword>immunization</keyword>
</DOC>